The abstract is read at the publisher; the summary is JClub's.
In Ethiopia, three consecutive daily doses of albendazole-ivermectin co-formulation deplete Enterobacteriaceae—especially Escherichia coli—and reduce E. coli-linked resistance genes and metabolic pathways.
- Why it matters: Helminth control depends on mass anthelmintic treatment, but microbiome and resistome effects that may shape treatment response are not well defined.
- What they did: Using genome-resolved metagenomics on 858 paired stool metagenomes from 429 children in the ALIVE trial (Ethiopia and Mozambique), they profiled microbiome, resistome, and function at baseline and after albendazole or co-formulation.
- The result: Baseline composition differed more by country than infection status and was not linked to albendazole efficacy or adverse events, while genome-resolved analysis of over 22,000 metagenome-assembled genomes confirmed the E. coli depletion across multiple strain-level populations.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.